Algert Global LLC Buys Shares of 2,549 Ascendis Pharma A/S $ASND

Key Points

• Algert Global LLC acquired a new stake in Ascendis Pharma A/S, purchasing 2,549 shares valued at approximately $397,000 in the first quarter.
• Ascendis Pharma A/S experienced a 0.8% increase in stock trading, with current shares priced at $194.30 and a market capitalization of $11.89 billion.
• The company reported $216.28 million in revenue for Q2, surpassing the consensus estimate of $163.17 million, alongside a narrower loss of ($0.93) earnings per share compared to an expected ($1.42).

Algert Global LLC purchased a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 2,549 shares of the biotechnology company's stock, valued at approximately $397,000.

Other large investors have also made changes to their positions in the company. HighTower Advisors LLC boosted its position in shares of Ascendis Pharma A/S by 413.1% during the 1st quarter. HighTower Advisors LLC now owns 18,032 shares of the biotechnology company's stock worth $2,810,000 after acquiring an additional 14,518 shares in the last quarter. Pursue Wealth Partners LLC acquired a new stake in shares of Ascendis Pharma A/S during the 1st quarter worth approximately $226,000. Sigma Planning Corp acquired a new stake in shares of Ascendis Pharma A/S during the 1st quarter worth approximately $236,000. Diversify Advisory Services LLC acquired a new stake in Ascendis Pharma A/S in the first quarter valued at approximately $332,000. Finally, Diversify Wealth Management LLC acquired a new stake in Ascendis Pharma A/S in the first quarter valued at approximately $998,000.

Ascendis Pharma A/S Price Performance

NASDAQ ASND traded down $1.09 during mid-day trading on Friday, reaching $192.81. 181,562 shares of the stock were exchanged, compared to its average volume of 490,314. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $199.99. The stock has a 50 day simple moving average of $179.84 and a 200-day simple moving average of $165.40. The stock has a market cap of $11.80 billion, a P/E ratio of -37.37 and a beta of 0.41.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, topping analysts' consensus estimates of ($1.42) by $0.49. The firm had revenue of $216.28 million for the quarter, compared to the consensus estimate of $163.17 million. Sell-side analysts anticipate that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Analysts Set New Price Targets

ASND has been the topic of a number of research analyst reports. Citigroup restated a "buy" rating and issued a $290.00 target price (up previously from $243.00) on shares of Ascendis Pharma A/S in a research report on Friday, August 8th. Oppenheimer restated an "outperform" rating and issued a $224.00 target price (up previously from $215.00) on shares of Ascendis Pharma A/S in a research report on Friday, June 13th. Cowen restated a "buy" rating on shares of Ascendis Pharma A/S in a research report on Friday, August 8th. Stifel Nicolaus raised their target price on shares of Ascendis Pharma A/S from $212.00 to $254.00 and gave the company a "buy" rating in a research report on Friday, August 8th. Finally, Wall Street Zen upgraded shares of Ascendis Pharma A/S from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Fifteen research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Ascendis Pharma A/S has a consensus rating of "Buy" and an average price target of $243.36.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.